* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on August 8.
* The South Jordan Utah-based company is expected to report
a
2.8% increase in revenue to $72.634 million from $70.63 million
a year ago, according to the mean estimate from 16 analysts,
based on Refinitiv data. The company's guidance on May 9 2023,
for the period ended June 30, was for revenue between $70.30
million and $74.30 million.
* Refinitiv's mean analyst estimate for Health Catalyst Inc
is
for breakeven results per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $16, above its last closing price of $13.82.
The company's guidance on May 9 2023 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD70.3 million and USD4.75 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.04 -0.04 0.05 Beat 222.9
Dec. 31 2023 -0.11 -0.11 -0.05 Beat 55.8
Sep. 30 2022 -0.18 -0.19 -0.13 Beat 32.8
Jun. 30 2022 -0.09 -0.10 -0.03 Beat 70.2
Mar. -0.09 -0.11 -0.06 Beat 47.6
31 2022
Dec. 31 2021 -0.16 -0.21 -0.19 Beat 10.2
Sep. 30 2021 -0.21 -0.22 -0.18 Beat 17.2
Jun. 30 2021 -0.14 -0.14 0.00 Beat 100
This summary was machine generated August 5 at 02:07 GMT. All
figures in US dollars unless otherwise stated